Journal of Glaucoma

Skip Navigation LinksHome > October/November 2013 - Volume 22 - Issue 8 > Impact of Age, Diagnosis, and History of Glaucoma Surgery on...
Journal of Glaucoma:
doi: 10.1097/IJG.0b013e31824d4fb9
Original Studies

Impact of Age, Diagnosis, and History of Glaucoma Surgery on Outcomes in Pediatric Patients Treated With Latanoprost

Maeda-Chubachi, Tomoko MD, PhD*; Chi-Burris, Katherine MPH; Simons, Brad MD, PhD; Brémond-Gignac, Dominique MD, PhD§; Freedman, Sharon MD; Khaw, Peng T. MD, PhD; Wirostko, Barbara MD#; Yan, Eric PhD; the A6111137 Study Group

Supplemental Author Material
Collapse Box


Purpose: To evaluate the impact of age, glaucoma-specific diagnosis, and history of prior glaucoma surgery on outcomes in pediatric patients treated with latanoprost monotherapy.

Patients and Methods: Prospective, randomized, double-masked 12-week, multicenter study included individuals 18 years or younger with glaucoma. Subjects stratified by age (0 to <3, 3 to <12, 12 to 18 y), diagnosis [primary congenital glaucoma (PCG) vs. non-PCG], and baseline intraocular pressure (IOP; 22 to <27, 27 to 31, >31 mm Hg), and randomized (1:1) to latanoprost vehicle (8 AM) and latanoprost 0.005% (8 PM) or timolol 0.5% (or 0.25% for those less than 3 y old; 8 AM/8 PM). IOP and safety assessments performed and adverse events recorded at baseline, weeks 1, 4, 12. Post hoc analyses in age-specific and diagnosis-specific groups of latanoprost-treated subjects were conducted (intent-to-treat population).

Results: Sixty-eight subjects were treated with latanoprost (0 to <3, n=17; 3 to <12, n=26; 12 to 18, n=25); 82%, 42%, and 24%, respectively, had a primary diagnosis of PCG. Among Non-PCG subjects, 0% (0/3), 47% (7/15), and 63% (12/19) had a primary diagnosis of juvenile open-angle glaucoma in the 0 to <3, 3 to <12, and 12 to 18 year cohorts, respectively. Mean percent IOP reductions from baseline at week 12 were 22%, 24%, and 30% in the youngest through oldest age groups, respectively (P=0.3600). At week 12, a higher responder rate (≥15% IOP reduction) was observed in the non-PCG than in the PCG group (70% vs. 45%, respectively; P=0.0361). Latanoprost was well tolerated.

Conclusion: All age and diagnosis subgroups showed clinically relevant (>20%) mean IOP reduction at week 12 with latanoprost monotherapy.

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.